Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis

EMBO Journal

Volumn 16, Issue 3, 1997, Pages 504-514

  Desaintes, Christian ^a   Demeret, Caroline ^a   Goyat, Sylvain ^a   Yaniv, Moshe ^a   Thierry, Françoise ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Apoptosis; Cell cycle; HPV18 E2; p53; Transcription

Indexed keywords

PROTEIN P53; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL DEATH; GENE MUTATION; HELA CELL; HUMAN; HUMAN CELL; LIFE CYCLE; MITOSIS INHIBITION; NONHUMAN; ONCOGENE; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROMOTER REGION; TRANSACTIVATION; VIRUS CELL INTERACTION; VIRUS REPLICATION; WART VIRUS;

APOPTOSIS; BLOTTING, WESTERN; BOVINE PAPILLOMAVIRUS 1; CHLORAMPHENICOL O-ACETYLTRANSFERASE; DNA-BINDING PROTEINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; G1 PHASE; GENE EXPRESSION REGULATION, VIRAL; GENES, REPORTER; HELA CELLS; HUMANS; MICROSCOPY, FLUORESCENCE; MUTATION; ONCOGENE PROTEINS, VIRAL; PROMOTER REGIONS (GENETICS); TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; VIRAL PROTEINS;

BOVINAE; BOVINE PAPILLOMAVIRUS; BOVINE PAPILLOMAVIRUS TYPE 1; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 0031025688     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/16.3.504     Document Type: Article

References (67)

1. Almasan, A., Yin, Y., Kelly, R.E., Lee, E.Y., Bradley, A., Li, W., Bertino, J.R. and Wahl, G.M. (1995) Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc. Natl Acad. Sci. USA, 92, 5436-5440.
2. Androphy, E.J., Lowy, D.R. and Schiller, J.T. (1987) Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA. Nature, 325, 70-73.
3. Baker, S.J., Markowitz, S., Fearon, E.R., Willson, J.K. and Vogelstein, B. (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science, 249, 912-915.
4. Barak, Y., Juven, T., Haffner, R. and Oren, M. (1993) mdm2 expression is induced by wild type p53 activity. EMBO J., 12, 461-468.
5. Benson, J.D. and Howley, P.M. (1995) Amino-terminal domains of the bovine papillomavirus type 1 E1 and E2 proteins participate in complex formation. J. Virol., 69, 4364-4372.
6. Bernard, B.A., Bailly, C., Lenoir, M.C., Darmon, M., Thierry, F. and Yaniv, M. (1989) The human papillomavirus type 18 (HPV18) E2 gene product is a repressor of the HPV18 regulatory region in human keratinocytes. J. Virol., 63, 4317-4324.
7. Berumen, J., Casas, L., Segura, E., Amezcua, J. and Garcia-Carranca, A. (1994) Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to the retention of E1/E2 genes. Int. J. Cancer, 56, 640-645.
8. Bosch, F.X., Schwarz, E., Boukamp, P., Fusenig, N.E., Bartsch, D. and zur Hausen, H. (1990) Suppression in vivo of human papillomavirus type 18 E6-E7 gene expression in nontumorigenic HeLa X fibroblast hybrid cells. J. Virol., 64, 4743-4754.
9. Butz, K., Shahabeddin, L., Geisen, C., Spitkovsky, D., Ullmann, A. and Hoppe-Seyler, F. (1995) Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene, 10, 927-936.
10. Caelles, C., Helmberg, A. and Karin, M. (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature, 370, 220-223.
11. Chiang, C.M., Ustav, M., Stenlund, A., Ho, T.F., Broker, T.R. and Chow, L.T. (1992) Viral E1 and E2 proteins support replication of homologous and heterologous papillomavirus origins. Proc. Natl Acad. Sci. USA, 89, 5799-5803.
12. Crook, T., Fisher, C., Masterson, P.J. and Vousden, K.H. (1994) Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene, 9, 1225-1230.
13. de Villiers, E.M. (1994) Human pathogenic papillomavirus types: an update. Curr. Top. Microbiol. Immunol., 186, 1-12.
14. Del Vecchio, A.M., Romanczuk, H., Howley, P.M. and Baker, C.M. (1992) Transient replication of human papillomavirus DNAs. J. Virol., 66, 5949-5958.
15. Demeret, C., Yaniv, M. and Thierry, F. (1994) The E2 transcriptional repressor can compensate for Sp1 activation of the human papillomavirus type 18 early promoter. J. Virol., 68, 7075-7082.
16. Desaintes, C., Hallez, S., Van Alphen, P. and Burny, A. (1992) Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type 16. J. Virol., 66, 325-333.
17. Desaintes, C., Hallez, S., Detremmerie, O. and Burny, A. (1995) Wild-type p53 down-regulates transcription from oncogenic human papillomavirus promoters through the epithelial specific enhancer Oncogene, 10, 2155-2161.
18. Diller, L. et al. (1990) p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell Biol., 10, 5772-5781.
19. Dostatni, N., Thierry, F. and Yaniv, M. (1988) A dimer of BPV-1 E2 containing a protease resistant core interacts with its DNA target EMBO J., 7, 3807-3816.
20. Dostatni, N., Lambert, P.F., Sousa, R., Ham, J., Howley, P.M. and Yaniv, M. (1991) The functional BPV1 E2 trans-activating protein can act as a repressor by preventing formation of the initiation complex. Genes Dev., 5, 1657-1671.
21. Dowhanick, J.J., McBride, A.A. and Howley, P.M. (1995) Suppression of cellular proliferation by the papillomavirus E2 protein. J. Virol., 69, 7791-7799.
22. Dürst, M., Glitz, D., Schneider, A. and zur Hausen, H. (1992) Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology, 189, 132-140.
23. Dyson, N., Howley, P.M., Münger, K. and Harlow, E. (1989) The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science, 243, 934-937.
24. Eizenberg, O., Faber-Elman, A., Gottlieb, E., Oren, M., Rotter, V. and Schwartz, M. (1995) Direct involvement of p53 in programmed cell death of oligodendrocytes. EMBO J., 14, 1136-1144.
25. El-Deiry, W. et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
26. Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R. and Prives, C. (1992) Wild-type p53 activates transcription in vitro. Nature, 358, 83-86.
27. Funk, W.D., Pak, D.T., Karas, R.H., Wright, W.E. and Shay, J.W. (1992) A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell Biol., 12, 2866-2871.
28. Garcia-Carranca, A., Thierry, F. and Yaniv, M. (1988) Interplay of viral and cellular proteins along the long control region of human papillomavirus type 18. J. Virol., 62, 4321-4330.
29. Giri, I. and Yaniv, M. (1988) Structural and mutational analysis of E2 trans-activating proteins of papillomaviruses reveals three distinct functional domains. EMBO J., 7, 2823-289.
30. Haas-Kogan, D.A., Kogan, S.C. Levi, D., Dazin, P., T'Ang, A., Fung, Y.K. and Israel, M.A. (1995) Inhibition of apoptosis by the retinoblastoma gene product. EMBO J., 14, 461-472.
31. Ham, J., Dostatni, N., Arnos, F. and Yaniv, M. (1991a) Several different upstream promoter elements can potentiate transactivation by the BPV1 E2 protein. EMBO J., 10, 2931-2940.
32. Ham, J., Dostatni, N., Gauthier, J.M. and Yaniv, M. (1991b) The papillomavirus E2 protein: a factor with many talents. Trends Biochem. Sci., 16, 440-444.
33. Harper, J.W. et al. (1995) Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell, 6, 387-400.
34. Haupt, Y., Rowan, S., Shaulian, E., Vousden, K.H. and Oren, M. (1995) Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev., 9, 2170-2183.
35. Haupt, Y., Barak, Y. and Oren, M. (1996) Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J., 15, 1596-1606.
36. Hegde, R.S., Grossman, S.R., Laimins, L.A. and Sigler, P.B. (1992) Crystal structure at 1.7 Å of the bovine papillomavirus-1 E2 DNA-binding domain bound to its DNA target. Nature, 359, 505-512.
37. Hupp, T.R. and Lane, D.P. (1994) Allosteric activation of latent p53 tetramers. Curr. Biol., 4, 865-875.
38. Hupp, T.R., Meek, D.W., Midgley, C.A. and Lane, D.P. (1992) Regulation of the specific DNA binding function of p53. Cell, 71, 875-886.
39. Hupp, T.R., Sparks, A. and Lane, D.P. (1995) Small peptides activate the latent sequence-specific DNA binding function of p53. Cell, 83, 237-245.
40. Hwang, E.-S., Riese, D.J., Settleman, J., Nilson, L.A., Honig, J., Flynn, S. and DiMaio, D. (1993) Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine regulatory gene. J. Virol., 67, 3720-3729.
41. Hwang, E.-S., Naeger, L.K. and DiMaio, D. (1996) Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene. Oncogene, 12, 795-803.
42. Kastan, M.B., Zhan, Q., El-Diery, W., Carrier, F., Jacks, T., Walsh, W.V., Plunkett, B.S., Vogelstein, B. and Fornace, A.J. (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71, 587-597.
43. Kern, S.E., Pietenpol, J.A., Thiagalingam, S., Seymour, A., Kinzler, K.W. and Vogelstein, B. (1992) Oncogenic forms of p53 inhibit p53-regulated gene expression. Science, 256, 827-830.
44. Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V. and Kastan, M.B. (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl Acad. Sci. USA, 89, 7491-7495.
45. Lambert, P.F., Spalholz, B.A. and Howley, P.M. (1987) A transcriptional repressor encoded by BPV-1 shares a common carboxy-terminal domain with the E2 transactivator. Cell, 50, 69-78.
46. Lambert, P.F., Hubbert, N.L., Howley, P.M. and Schiller, J.T. (1989) Genetic assignment of multiple E2 gene products in bovine papillomavirus-transformed cells. J. Virol., 63, 3151-3154.
47. Le Moal, M.A., Yaniv, M. and Thierry, F. (1994) The bovine papillomavirus type 1 (BPV1) replication protein E1 modulates transcriptional activation by interacting with BPV1 E2. J. Virol., 68, 1085-1093.
48. McBride, A.A., Byrne, J.C. and Howley, P.M. (1989) E2 polypeptides encoded by bovine papillomavirus type 1 form dimers through the common carboxyl-terminal domain: transactivation is mediated by the conserved amino-terminal domain. Proc. Natl Acad. Sci. USA, 86, 510-514.
49. Momand, J., Zambetti, G.P., Olson, D.C., George, D. and Levine, A.J. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-1245.
50. Pietenpol, J.A., Tokino, T., Thiagalingam, S., El-Diery, W., Kinzler, K.W. and Vogelstein, B. (1994) Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl Acad. Sci. USA, 91, 1998-2002.
51. Rowan, S., Ludwig, R.L., Haupt, Y., Bates, S., Lu, X., Oren, M. and Vousden, K.H. (1996) Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J., 15, 827-838.
52. Scheffner, M., Werness, B.A., Huibregtse, J.M., Levine, A.J. and Howley, P.M. (1990) The E6 oncoprotein encoded by human papillomaviruses types 16 and 18 promotes the degradation of p53. Cell, 63, 1129-1136.
53. Scheffner, M., Münger, K., Byrne, J.C. and Howley, P.M. (1991) The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl Acad. Sci. USA, 88, 5523-5527.
54. Schwarz, E., Freese, U.K., Gissmann, L., Mayer, W., Roggenbuck, B., Stremlau, A. and zur Hausen, H. (1985) Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature, 314, 111-114.
55. Shaulian, E., Zauberman, A., Ginsberg, D. and Oren, M. (1992) Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell Biol., 12, 5581-5592.
56. Takenaka, I., Morin, F., Seizinger, B.R. and Kley, N. (1995) Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J. Biol. Chem., 270, 5405-5411.
57. Tanaka, M. and Herr, W. (1990) Differential transcriptional activation by Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphorylation. Cell, 60, 375-386.
58. Thierry, F. and Howley, P.M. (1991) Functional analysis of E2-mediated repression of the HPV18 P105 promoter. New Biol., 3, 90-100.
59. Thierry, F. and Yaniv, M. (1987) The BPV1-E2 trans-acting protein can be either an activator or a repressor of the HPV18 regulatory region. EMBO J., 6, 3391-3397.
60. Thierry, F., Garcia-Carranca, A. and Yaniv, M. (1987a) Elements that control the transcription of genital human papillomavirus type 18. Cancer Cells, 5, 23-32.
61. Thierry, F., Heard, J.M., Dartmann, K. and Yaniv, M. (1987b) Characterization of a transcriptional promoter of human papillomavirus 18 and modulation of its expression by simian virus 40 and adenovirus early antigens. J. Virol., 61, 134-142.
62. Thierry, F., Dostatni, N., Arnos, F. and Yaniv, M. (1990) Cooperative activation of transcription by bovine papillomavirus type 1 E2 can occur over a large distance. Mol. Cell. Biol., 10, 4431-4437.
63. Ustav, M. and Stenlund, A. (1991) Transient replication of BPV-1 requires two viral polypeptides encoded by the E1 and E2 open reading frames. EMBO J., 10, 449-457.
64. Wagner, A.J., Kokontis, J.M. and Hay, N. (1994) Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev., 8, 2817-2830.
65. Wang, Y. and Prives, C. (1995) Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature, 376, 88-91.
66. Xiong, Y., Hannon, G.J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D. (1993) p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704.
67. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A. and Oren, M. (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature, 352, 345-347.